New drug WTX-330 aims to boost immune system against tough cancers

NCT ID NCT06939283

First seen Feb 15, 2026 · Last updated May 14, 2026 · Updated 13 times

Summary

This study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The main goals are to find safe dose levels and see if the drug can shrink tumors. Researchers will also measure how the drug affects the immune system and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • HonorHealth Research Institute

    Scottsdale, Arizona, 85258, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • NEXT Oncology

    San Antonio, Texas, 78229, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

Conditions

Explore the condition pages connected to this study.